Clinical Trials Logo

Non-Hodgkins Lymphoma clinical trials

View clinical trials related to Non-Hodgkins Lymphoma.

Filter by:

NCT ID: NCT00179673 Completed - Clinical trials for Non-Hodgkins Lymphoma

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Start date: August 2005
Phase: Phase 2
Study type: Interventional

Participants who qualify will receive lenalidomide daily on days 1-21 of every 28 day cycle. Treatment will continue for up to 52 weeks or until disease progression; participants who achieve a complete response (CR) will receive an additional 2 cycles of treatment prior to discontinuation. Participants will be followed for progression free survival following discontinuation from the treatment phase

NCT ID: NCT00179660 Completed - Clinical trials for Non-Hodgkins Lymphoma

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Start date: August 2005
Phase: Phase 2
Study type: Interventional

To determine the activity of lenalidomide in relapsed or refractory aggressive NHL.